We aim to provide members with both general and haematology specific up-to-date COVID-19 information.
This advice is for healthcare professionals. Patients looking for further information on their condition are advised to speak to their healthcare providers, who are best placed to answer specific questions.
Patients may also be able to get information from their patient support groups, some of them can be found listed here.
WHO issued a statement on 5 May 2023 that COVID-19 is now an established and ongoing health issue which no longer constitutes a public health emergency of international concern (PHEIC). Covid-19 vaccinations will continue, with relevance to certain haematology patient groups.
This page will be reviewed every day and updated as necessary.
If you would like to add any resources, please email [email protected].
This page covers what we know so far about covid vaccine effectiveness in people with different types of blood cancer, and what Blood Cancer UK are doing in this area.
Additional provision of support for Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) patients leaflet provided by Thrombosis UK
Guidance produced by the UK ITP Forum Working Party on ITP/ITP relapse following Covid-19 vaccination.
There is now emerging evidence of a small risk of ITP or ITP relapse following Covid-19 vaccination. The UK ITP Forum has produced guidance for clinicians managing such cases. This is a live document subject to updates as more is learnt about the condition.
An information sheet for patients with Immune Thrombocytopenia (ITP) scheduled for Covid-19 vaccination.
The UK ITP Forum, has provided information for adult patients with immune thrombocytopenia in the setting of COVID-19.
Click here to read the document
The Government has announced changes to its policy on coronavirus testing in England. Patients eligible for COVID-19 treatments through a COVID Medicines Delivery Unit (CMDU) will now need to use a Lateral Flow Test, which will be supplied to them by UKHSA, for use at home if they have symptoms of COVID-19.
Key information you need to know can be found here.
A multi-stakeholder coalition consisting of representatives from the global patient advocacy and clinical community has formed the International COVID-19 Blood Cancer Coalition (ICBCC) to address the specific impact of the pandemic on immunocompromised blood cancer patients (both acute and
chronic), like those living with Chronic Lymphocytic Leukemia (CLL), and to recommend solutions and
actions to mitigate those risks.
BSH has endorsed their PATIENT IMPACT STATEMENT AND RECOMMENDATIONS: Protecting immunocompromised blood cancer patients during the COVID-19 pandemic which can be found here.